专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010021423A1 METHOD FOR DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA 审中-公开
标题翻译：诊断患有肝细胞癌的患者术后复发的方法
公开(公告)号：WO2010021423A1
公开(公告)日：2010-02-25
申请号：PCT/KR2008/004996
申请日：2008-08-26
申请人： UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION , CHUNG, Young Hwa , YU, Eun Sil , RYU, Soo Hyung , KIM, Kyu Won , KIM, Jeong A.
发明人： CHUNG, Young Hwa , YU, Eun Sil , RYU, Soo Hyung , KIM, Kyu Won , KIM, Jeong A.
IPC分类号： G01N33/574
CPC分类号： G01N33/57438 , G01N2800/54
摘要： Provided are a method of diagnosing the recurrence or possibility of recurrence of hepa¬ tocellular carcinoma after hepatocellular carcinoma surgery and a method of screening a drug for preventing the recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and treating hepatocellular carcinoma. Specifically, the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery is diagnosed and a drug for preventing the recurrence of hepatocellular carcinoma after surgery and treating hepatocellular carcinoma is screened, by measuring expression levels of a metastatic tumor antigen 1 or metastasis associated 1 (MTAl) protein in a biological sample taken from a patient in which hep¬ atocellular carcinoma recurs or is likely to recur after hepatocellular carcinoma surgery and comparing the measured expression levels of the MTAl protein with those of a normal control group.
摘要翻译：提供了一种诊断肝细胞癌手术后肝细胞癌复发或复发可能性的方法，以及筛选肝细胞癌手术治疗肝细胞癌后肝细胞癌复发的药物方法。具体来说，通过测定转移性肿瘤抗原1或转移相关的表达水平，筛选肝细胞癌手术后肝细胞癌复发或复发的可能性，并筛选手术后肝细胞癌复发的药物（MTA1）蛋白质，其中肝细胞癌复发或可能在肝细胞癌手术后复发的患者中获取，并比较测量的MTA1蛋白表达水平与正常对照组的表达水平。

2. 发明申请

WO1995023604A1 CELL GROWTH STIMULATING COMPOSITIONS CONTAINING ALOESIN 审中-公开
标题翻译：含有ALOESIN的细胞生长刺激组合物
公开(公告)号：WO1995023604A1
公开(公告)日：1995-09-08
申请号：PCT/KR1995000016
申请日：1995-03-02
申请人： NAMYANG ALOE CO., LTD. , KIM, Kyeong, Ho , PARK, Jeong, Hill , SUNG, Chung, Ki , KIM, Jin, Woong , CHOI, Jae, Sue , LEE, Seung, Ki , KIM, Yeong, Shik , SON, Byeong, Hwa , CHUNG, Myung, Hee , PARK, Young, In , KIM, Kyu, Won , LEE, Chong, Kil
发明人： NAMYANG ALOE CO., LTD.
IPC分类号： A61K31/70
CPC分类号： A61K31/70 , A61K8/602 , A61Q19/00
摘要： The present invention relates to a cell growth stimulating composition containing aloesin as an active ingredient. More specifically, the present invention relates to a composition for stimulating cell growth, especially for stimulating epidermal cells and hepatic cells, which contains aloesin as an active ingredient. Aloesin is a component of Aloe vera, for which an effect for blocking ultraviolet ray from skin and an activity as mushroom tyrosinase inhibitor have been disclosed in the prior art. However, accordint to the present invention, it has now been identified that aloesin has the novel pharmacological use as a cell growth stimulating agent which has never been disclosed in the prior art.
摘要翻译：本发明涉及含有芦荟素作为活性成分的细胞生长刺激组合物。更具体地，本发明涉及用于刺激细胞生长的组合物，特别是用于刺激含有芦荟素作为活性成分的表皮细胞和肝细胞。芦荟是芦荟的成分，现有技术已经公开了从皮肤阻断紫外线的效果和作为蘑菇酪氨酸酶抑制剂的活性。然而，根据本发明，现在已经确定，芦荟素具有新的药理学用途作为细胞生长刺激剂，其从未在现有技术中公开。

3. 发明申请

WO2006073265A1 COMPOSITION COMPRISING AN EXTRACT OF GRAMINEAE PLANT FOR THE PREVENTION AND TREATMENT OF ISCHEMIC DISEASES AND DEGENERATIVE BRAIN DISEASES AND THE USE THEREOF 审中-公开
标题翻译：包含用于预防和治疗异位性疾病和变应性脑疾病的植物植物提取物的组合物及其用途
公开(公告)号：WO2006073265A1
公开(公告)日：2006-07-13
申请号：PCT/KR2006/000027
申请日：2006-01-04
申请人： HYPOXI CO., LTD. , SUN MOK INSTITUTE EDUCATION FOUNDATION , LEE, Jong Won , HWANG, Ki-chul , HAN, Hyung Soo , LIM, Sun Ha , LEE, Hyeong-kyu , LEE, Sang Hyuk , KIM, Kyu Won , JUN, Hyung Oh , KIM, Hyun Jeong , LEE, In-seon , YANG, Chae Ha
发明人： LEE, Jong Won , HWANG, Ki-chul , HAN, Hyung Soo , LIM, Sun Ha , LEE, Hyeong-kyu , LEE, Sang Hyuk , KIM, Kyu Won , JUN, Hyung Oh , KIM, Hyun Jeong , LEE, In-seon , YANG, Chae Ha
IPC分类号： A61K36/899 , A23L1/29 , A61P25/28
CPC分类号： A61K36/899 , A23L33/105 , A23V2002/00 , A23V2200/322 , A23V2250/21
摘要： The present invention relates to a composition comprising extracts of Gramineae plant that improves cell viability under hypoxic conditions by inhibiting apoptosis. Thus, the extract of Triticum aestivum L., one of the Gramineae plant, of the present invention, in particular, prevents damage of brain, heart and kidney in animal models of ischemic diseases, and it also improves memory in an animal model of Alzheimer's disease. Therefore, a composition comprising extracts of Gramineae can be used as therapeutic agents or health care foods for preventing and treating ischemic diseases and degenerative brain diseases.
摘要翻译：本发明涉及包含通过抑制细胞凋亡在缺氧条件下改善细胞活力的禾本科植物提取物的组合物。因此，特别地，本发明的禾本科植物之一的小麦Triticum aestivum L.的提取物防止脑，心脏和肾脏在缺血性疾病的动物模型中的损伤，并且还改善了阿尔茨海默病动物模型中的记忆疾病。因此，包含禾本科植物提取物的组合物可用作预防和治疗缺血性疾病和退行性脑疾病的治疗剂或保健食品。

4. 发明申请

WO2012115439A3 COMPOSITION COMPRISING EXPRESSION OR ACTIVITY REGULATORS OF AKAP12 FOR TREATING CENTRAL NERVE SYSTEM DISEASES 审中-公开
标题翻译：包含AKAP12表达或活化调节因子治疗中枢神经系统疾病的组合物
公开(公告)号：WO2012115439A3
公开(公告)日：2012-12-13
申请号：PCT/KR2012001319
申请日：2012-02-21
申请人： SNU R&DB FOUNDATION , KIM KYU WON , CHA JONG HO
发明人： KIM KYU WON , CHA JONG HO
IPC分类号： A61K38/16 , A61K38/18 , A61P9/00 , A61P25/00
CPC分类号： A61K45/06
摘要： Disclosed is a pharmaceutical composition for the treatment of central nervous system diseases which comprises an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as an active ingredient. Also, a method is provided for treating central nervous system diseases using the pharmaceutical composition. Having the ability to up- or down-regulate the formation of fibrotic-glial scars which are absolutely central to the regulation of central nervous system diseases, the expression or activity regulator of AKAP12 can be used to effectively treat central nervous system diseases by reducing excessive inflammation-induced secondary injury and by promoting the regeneration of the neural network. Ultimately, the expression or activity regulator of AKAP12 is expected to be used in the treatment and prognosis improvement of central nervous system diseases including post-traumatic stress syndrome, stroke, and spinal injury.
摘要翻译：公开了用于治疗中枢神经系统疾病的药物组合物，其包含作为活性成分的AKAP12（A激酶锚定蛋白12）的表达或活性调节剂。另外，提供了使用药物组合物治疗中枢神经系统疾病的方法。具有上调或下调对中枢神经系统疾病调节绝对中心的纤维化神经胶质瘢痕形成的能力，AKAP12的表达或活性调节剂可用于通过减少过量来有效治疗中枢神经系统疾病炎症引起的继发性损伤，并促进神经网络的再生。最终，AKAP12的表达或活性调节剂预期用于中枢神经系统疾病的治疗和预后改善，包括创伤后应激综合征，中风和脊髓损伤。

5. 发明申请

WO2012115439A9 COMPOSITION COMPRISING EXPRESSION OR ACTIVITY REGULATORS OF AKAP12 FOR TREATING CENTRAL NERVE SYSTEM DISEASES 审中-公开
标题翻译：包含AKAP12表达或活性调节剂的组合物用于治疗中枢神经系统疾病
公开(公告)号：WO2012115439A9
公开(公告)日：2012-10-26
申请号：PCT/KR2012001319
申请日：2012-02-21
申请人： SNU R&DB FOUNDATION , KIM KYU WON , CHA JONG HO
发明人： KIM KYU WON , CHA JONG HO
IPC分类号： A61K38/16 , A61K38/18 , A61P9/00 , A61P25/00
CPC分类号： A61K45/06
摘要： Disclosed is a pharmaceutical composition for the treatment of central nervous system diseases which comprises an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as an active ingredient. Also, a method is provided for treating central nervous system diseases using the pharmaceutical composition. Having the ability to up- or down-regulate the formation of fibrotic-glial scars which are absolutely central to the regulation of central nervous system diseases, the expression or activity regulator of AKAP12 can be used to effectively treat central nervous system diseases by reducing excessive inflammation-induced secondary injury and by promoting the regeneration of the neural network. Ultimately, the expression or activity regulator of AKAP12 is expected to be used in the treatment and prognosis improvement of central nervous system diseases including post-traumatic stress syndrome, stroke, and spinal injury.
摘要翻译：公开了用于治疗中枢神经系统疾病的药物组合物，其包含作为活性成分的AKAP12（A激酶锚定蛋白12）的表达或活性调节剂。而且，提供了使用该药物组合物治疗中枢神经系统疾病的方法。具有上调或下调对中枢神经系统疾病的调节绝对中心的纤维化 - 胶质瘢痕的形成的能力，AKAP12的表达或活性调节剂可用于通过减少过量来有效治疗中枢神经系统疾病炎症诱导的继发性损伤以及促进神经网络的再生。最终，AKAP12的表达或活性调节剂有望用于包括创伤后应激综合征，中风和脊髓损伤在内的中枢神经系统疾病的治疗和预后改善。

6. 发明申请

WO2012115439A2 COMPOSITION COMPRISING EXPRESSION OR ACTIVITY REGULATORS OF AKAP12 FOR TREATING CENTRAL NERVE SYSTEM DISEASES 审中-公开
标题翻译：包含AKAP12表达或活性调节剂的组合物用于治疗中枢神经系统疾病
公开(公告)号：WO2012115439A2
公开(公告)日：2012-08-30
申请号：PCT/KR2012/001319
申请日：2012-02-21
申请人： SNU R&DB FOUNDATION , KIM, Kyu Won , CHA, Jong Ho
发明人： KIM, Kyu Won , CHA, Jong Ho
IPC分类号： A61K38/16 , A61K38/18 , A61P25/00 , A61P9/00
CPC分类号： A61K45/06
摘要： Disclosed is a pharmaceutical composition for the treatment of central nervous system diseases which comprises an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as an active ingredient. Also, a method is provided for treating central nervous system diseases using the pharmaceutical composition. Having the ability to up- or down-regulate the formation of fibrotic-glial scars which are absolutely central to the regulation of central nervous system diseases, the expression or activity regulator of AKAP12 can be used to effectively treat central nervous system diseases by reducing excessive inflammation-induced secondary injury and by promoting the regeneration of the neural network. Ultimately, the expression or activity regulator of AKAP12 is expected to be used in the treatment and prognosis improvement of central nervous system diseases including post-traumatic stress syndrome, stroke, and spinal injury.
摘要翻译：公开了用于治疗中枢神经系统疾病的药物组合物，其包含作为活性成分的AKAP12（A-激酶锚定蛋白12）的表达或活性调节剂。而且，提供了使用该药物组合物治疗中枢神经系统疾病的方法。具有上调或下调对中枢神经系统疾病的调节绝对中心的纤维化 - 胶质瘢痕的形成的能力，AKAP12的表达或活性调节剂可用于通过减少过量来有效治疗中枢神经系统疾病炎症诱导的继发性损伤以及促进神经网络的再生。最终，AKAP12的表达或活性调节剂预计将用于包括创伤后应激综合征，中风和脊髓损伤在内的中枢神经系统疾病的治疗和预后改善。

7. 发明申请

WO2004110476A1 PHARMACEUTCAL COMPOSITION FOR TREATING OR PREVENTING DISORDERS OF BLOOD-BRAIN BARRIER 审中-公开
标题翻译：用于治疗或预防血液障碍的病人的药物组合物
公开(公告)号：WO2004110476A1
公开(公告)日：2004-12-23
申请号：PCT/KR2004/001415
申请日：2004-06-14
申请人： Seoul National University Industry Foundation , KIM, Kyu-Won , LEE, Sae-Won , KIM, Woo-Jean
发明人： KIM, Kyu-Won , LEE, Sae-Won , KIM, Woo-Jean
IPC分类号： A61K38/43
CPC分类号： A61K48/005 , A61K38/1709 , C12Q1/485 , G01N2500/10
摘要： Disclosed is a pharmaceutical composition for treating or preventing the Blood-Brain Barrier disorders by regulating brain angiogenesis and tight junction formation between brain endothelial cells, including an SSeCKS (src-suppressed C kinase substrate) protein or a recombinant expression vector expressing the protein.
摘要翻译：公开了通过调节脑内皮细胞（包括SSeCKS（src抑制的C激酶底物））蛋白或表达蛋白质的重组表达载体的脑内皮细胞之间的脑血管生成和紧密连接形成来治疗或预防血脑屏障障碍的药物组合物。

8. 发明申请

WO2004047852A1 PHARMACEUTICAL COMPOSITION FOR CONTROLING THE STABILITY OF HIF-1α 审中-公开
标题翻译：用于控制HIF-1α稳定性的药物组合物
公开(公告)号：WO2004047852A1
公开(公告)日：2004-06-10
申请号：PCT/KR2003/002577
申请日：2003-11-26
申请人： KIM, Kyu-Won , JEONG, Joo-Won
发明人： KIM, Kyu-Won , JEONG, Joo-Won
IPC分类号： A61K38/04
CPC分类号： A61K38/1709 , A61K38/45 , G01N2333/4703 , G01N2333/91057 , G01N2500/10
摘要： Disclosed are a pharmaceutical composition for promoting the degradation of hypoxia-inducible factor-1α (HIF-1α), which includes arrest-defective protein 1 (ARD1), a stimulator of ARD1 or a nucleic acid molecule to encode ARD1, a method of screening a compound stimulating ARDl expression, and a yeast two-hybrid system for screening a protein interacting HIF-1α. Also, the present invention discloses a pharmaceutical composition for inhibiting the degradation of HIF-1α, which includes an inhibitor of ARD1, an antibody specific to ARD1 or an antisense to hybridize with a polynucleotide encoding ARD1, and a method of screening a compound inhibiting ARDl expression.
摘要翻译：公开了用于促进缺氧诱导因子-1α（HIF-1α）降解的药物组合物，其包括阻滞缺陷蛋白1（ARD1），ARD1的刺激剂或编码ARD1的核酸分子，筛选方法刺激ARD1表达的化合物和用于筛选蛋白质相互作用的HIF-1α的酵母双杂交系统。此外，本发明公开了抑制HIF-1α降解的药物组合物，其包含ARD1抑制剂，ARD1特异性抗体或与编码ARD1的多核苷酸杂交的反义抗体，以及筛选抑制ARD1的化合物的方法表达。

9. 发明申请

WO2010067915A1 COMPOSITION COMPRISING EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN 1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE 审中-公开
标题翻译：包含NINJURIN 1的表达或活性抑制剂的组合物用于预防和治疗炎症疾病
公开(公告)号：WO2010067915A1
公开(公告)日：2010-06-17
申请号：PCT/KR2008/007629
申请日：2008-12-24
申请人： SNU R&DB FOUNDATION , KIM, Kyu-Won , LEE, Hyo-Jong
发明人： KIM, Kyu-Won , LEE, Hyo-Jong
IPC分类号： A61K38/16
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/14
摘要： The present invention relates to a composition comprising a Ninjurin 1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin 1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 ( angiopoietin-2 ), but reduces expression of Angl to induce apoptosis of vascular endothelial cells. In addition, Ninjurin 1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin 1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.
摘要翻译：本发明涉及包含用于预防和治疗炎性疾病的Ninjurin1表达或活性抑制剂的组合物。 Ninjurin 1蛋白在血管周围的巨噬细胞中特异性表达，增加细胞粘附和细胞粘附，增加Wnt7b（Wingless型MMTV整合位点家族，成员7B）和Ang2（血管生成素-2）的表达，的Ang1诱导血管内皮细胞凋亡。此外，Ninjurin 1蛋白在诱导炎症时上调，诱导iNOS表达以及NO产生增加。因此，Ninjurin 1蛋白质表达或激活抑制剂可以有效地用作预防和治疗炎性疾病的组合物的活性成分。

10. 发明申请

WO2009151304A3 COMPOSITION COMPRISED OF AKAP12 AND USES OF AKAP12 MUTANT ZEBRAFISH AS AN ANIMAL MODEL 审中-公开
标题翻译： AKAP12的组成和AKAP12突变体ZEBRAFISH作为动物模型的用途
公开(公告)号：WO2009151304A3
公开(公告)日：2010-03-04
申请号：PCT/KR2009003178
申请日：2009-06-12
申请人： SNU RDB FOUNDATION , KIM KYU-WON , KWON HYOUK-BUM
发明人： KIM KYU-WON , KWON HYOUK-BUM
IPC分类号： A61K38/16
CPC分类号： A61K38/1709
摘要： The present invention relates to a composition comprised of AKAP12 (A-Kinase anchoring protein 12) and to uses of AKAP12 mutant zebrafish as an animal model. More particularly, the following characteristics are noted in the present AKAP12 mRNA knockdown zebrafish: crooked or shortened tail, inability to move normally, non-uniform micro-vasculature in the brain, and change in heart shape with irregular and weak heartbeats. It also has various circulatory and genetic defects, such as hemorrhage from the ventricles of the heart, brain, and retina. All of these defects can be cured with AKAP12 injection. Therefore, AKAP12 can be used as an active component for a composition to prevent and heal circulatory and genetic defects that are caused by AKAP12 deficiency, and as a hemorrhage inhibitor. Further, the AKAP12 deficient mutant zebrafish can be useful as an animal model for verification of effectiveness of treatment for genetic defects in the circulatory system.
摘要翻译：本发明涉及由AKAP12（A-激酶锚定蛋白12）组成的组合物和AKAP12突变斑马鱼作为动物模型的用途。更具体地，在本发明的AKAP12mRNA敲除斑马鱼中注意到以下特征：弯曲或缩短的尾巴，不能正常移动，脑中不均匀的微血管系统以及具有不规则和弱心跳的心脏形状的变化。它还具有各种循环和遗传缺陷，例如来自心脏，脑和视网膜心室的出血。所有这些缺陷都可以用AKAP12注射固化。因此，AKAP12可用作组合物的活性成分，用于预防和治疗由AKAP12缺乏引起的循环和遗传缺陷，以及作为出血抑制剂。此外，AKAP12缺陷突变体斑马鱼可用作验证循环系统遗传缺陷治疗有效性的动物模型。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式